🔗 Share this article

The recently developed medications for gonorrhoea in decades are being viewed as a "huge turning point" in the battle against drug-resistant strains of the bacteria, according to scientists.

A Global Health Concern

Gonorrhoea infections are increasing around the world, with data suggesting over 82 million instances annually. Especially elevated rates are reported in the African continent and countries within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary advancement in the face of rising global incidence, increasing antimicrobial resistance and the extremely scarce treatment choices at this time.”

Public health authorities are increasingly worried about the increase in drug-resistant strains. The World Health Organization has listed it as a "critical concern". Ongoing monitoring revealed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Gain Clearance

Zoliflodacin, alternatively called Nuzolvence, was cleared by the US FDA in December for treating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Experts believe that specific application of this new drug will help delay the spread of drug resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin was the result of a innovative non-profit model for drug creation. The non-profit organisation GARDP collaborated with the pharmaceutical company its industry partner to develop it.

“This milestone signifies a significant shift in the management of multidrug-resistant gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Research Study Data and Worldwide Availability

According to findings detailed in a prominent scientific publication, the new drug successfully treated more than 90% of cases of the STI. This places it at an comparable level with the current standard treatment, which combines two antibiotics. The trial involved over 900 patients from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, the non-profit has the rights to license and sell the drug in many low-income and middle-income countries.

Doctors treating patients have voiced optimism. The availability of a easy-to-administer therapy like this is seen as a "critical tool" for gonorrhoea control. This is deemed vital to alleviate the strain of the infection for people and to prevent the spread of extremely resistant gonorrhoea globally.